Eli Lilly Stock Jumps on Blockbuster GLP-1 Sales and Raised 2026 Forecast

Eli Lilly and Company (NYSE:LLY) shares rallied nearly 4% in afternoon trading after the drugmaker announced second-quarter financial results that far surpassed Wall Street expectations, leading the company to raise its full-year revenue forecast.

Earnings and Revenue Beat

Eli Lilly reported a 48% year-over-year increase in second-quarter revenue, reaching $22.97 billion. This figure comfortably beat the analyst consensus of approximately $20.6 billion. Adjusted earnings per share came in at $8.38, also clearing analyst estimates by a significant margin, according to the company's report.

Following the strong performance, management lifted its full-year 2026 revenue guidance to a range of $85 billion to $87 billion, up from a prior forecast of $82 billion to $85 billion. This signals strong confidence in the company's ongoing growth trajectory.

GLP-1 Franchise Drives Growth

The exceptional results were overwhelmingly powered by the company's blockbuster GLP-1 franchise for diabetes and weight loss. Key sales figures for the quarter include:

Ad

• Mounjaro: Revenue surged 91% to $9.9 billion.
• Zepbound: The weight-loss treatment generated $4.9 billion in revenue.

Together, these two drugs accounted for roughly 65% of Eli Lilly's total quarterly revenue. The company’s new oral obesity pill, Foundayo, also contributed $98 million in its first full quarter of sales.

Market and Pipeline Context

Lilly's stock surge occurred on a day of mixed performance for the broader market, with the S&P 500 trading flat. The company's results stood in contrast to those of its primary rival, Novo Nordisk, which saw its shares decline a day earlier amid concerns over competition and disappointing sales for its oral Wegovy treatment.

Adding to the positive news, the U.S. Food and Drug Administration (FDA) recently granted Breakthrough Therapy designation to Lilly's oncology drug, olomorasib, for treating advanced pancreatic cancer. CEO David Ricks also noted that Medicare's new coverage for obesity drugs, which began in July, is "off to a strong start."